Eli Lilly's weight loss drug dramatically cuts risk of diabetes, company says

Eli Lilly’s antidiabetic medication Zepbound cuts the risk of developing Type 2 diabetes by 94 percent in prediabetic adults and those who are overweight or obese, the company said Tuesday.  

Prediabetic and overweight adults who took part in a Phase 3 trial study experienced a significantly reduced risk of progressing to Type 2 diabetes after receiving weekly injections of the medication’s main ingredient tirzepatide over three years compared to those who received a placebo, the company said in a release.